149 related articles for article (PubMed ID: 33583251)
41. Immunomodulatory analogues of thalidomide in the treatment of multiple myeloma.
Suppiah R; Srkalovic JG; Hussein MA
Clin Lymphoma Myeloma; 2006 Jan; 6(4):301-5. PubMed ID: 16507207
[TBL] [Abstract][Full Text] [Related]
42. Thalidomide and lenalidomide in multiple myeloma.
Mazumder A; Jagannath S
Best Pract Res Clin Haematol; 2006; 19(4):769-80. PubMed ID: 16997182
[TBL] [Abstract][Full Text] [Related]
43. Bortezomib and Thalidomide Treatment Results in Newly Diagnosed Transplant-Ineligible Multiple Myeloma Patients are Comparable in Long-Term Follow-Up.
Stork M; Sandecká V; Boichuk I; Adam Z; Krejci M; Brozova L; Sevcikova S; Pour L
Klin Onkol; 2019; 32(6):445-452. PubMed ID: 31842563
[TBL] [Abstract][Full Text] [Related]
44. Immunomodulatory drugs in multiple myeloma.
Zangari M; Elice F; Tricot G
Expert Opin Investig Drugs; 2005 Nov; 14(11):1411-8. PubMed ID: 16255679
[TBL] [Abstract][Full Text] [Related]
45. Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma.
Huang SY; Lin CW; Lin HH; Yao M; Tang JL; Wu SJ; Chen YC; Lu HY; Hou HA; Chen CY; Chou WC; Tsay W; Chou SJ; Tien HF
Ann Hematol; 2014 Aug; 93(8):1371-80. PubMed ID: 24687382
[TBL] [Abstract][Full Text] [Related]
46. Pomalidomide for multiple myeloma.
Fouquet G; Bories C; Guidez S; Renaud L; Herbaux C; Javed S; Facon T; Leleu X
Expert Rev Hematol; 2014 Dec; 7(6):719-31. PubMed ID: 25265911
[TBL] [Abstract][Full Text] [Related]
47. Phase II study of carfilzomib, thalidomide, and low-dose dexamethasone as induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma; the Carthadex trial.
Wester R; van der Holt B; Asselbergs E; Zweegman S; Kersten MJ; Vellenga E; van Marwijk Kooy M; de Weerdt O; Minnema M; Lonergan S; Palumbo A; Lokhorst H; Broijl A; Sonneveld P
Haematologica; 2019 Nov; 104(11):2265-2273. PubMed ID: 30948492
[TBL] [Abstract][Full Text] [Related]
48. [Reported use of thalidomide in multiple myeloma: presentation of problems in the Thaled® outpatient department].
Aimono Y; Sato W; Otani E; Isa S; Sawahata T; Onozaki M; Saito Y; Ebata S; Aoyama Y; Hakozaki M; Suzuki M; Kudo D; Monma Y; Chikatsu N; Shinagawa A
Gan To Kagaku Ryoho; 2011 Dec; 38(13):2579-84. PubMed ID: 22189222
[TBL] [Abstract][Full Text] [Related]
49. Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies.
Vallet S; Witzens-Harig M; Jaeger D; Podar K
Expert Opin Pharmacother; 2012 Mar; 13(4):473-94. PubMed ID: 22324734
[TBL] [Abstract][Full Text] [Related]
50. Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial.
Popat R; Brown SR; Flanagan L; Hall A; Gregory W; Kishore B; Streetly M; Oakervee H; Yong K; Cook G; Low E; Cavenagh J;
Lancet Haematol; 2016 Dec; 3(12):e572-e580. PubMed ID: 27843120
[TBL] [Abstract][Full Text] [Related]
51. Low venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect with thalidomide/lenalidomide-based therapy: review of data from phase 3 trials and studies of novel combination regimens.
Zangari M; Fink L; Zhan F; Tricot G
Clin Lymphoma Myeloma Leuk; 2011 Apr; 11(2):228-36. PubMed ID: 21575928
[TBL] [Abstract][Full Text] [Related]
52. Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma.
Kumar S; Gertz MA; Dispenzieri A; Lacy MQ; Geyer SM; Iturria NL; Fonseca R; Hayman SR; Lust JA; Kyle RA; Greipp PR; Witzig TE; Rajkumar SV
Mayo Clin Proc; 2003 Jan; 78(1):34-9. PubMed ID: 12528875
[TBL] [Abstract][Full Text] [Related]
53. Thalidomide treatment in multiple myeloma.
Strasser K; Ludwig H
Blood Rev; 2002 Dec; 16(4):207-15. PubMed ID: 12350364
[TBL] [Abstract][Full Text] [Related]
54. [Treatment of multiple myeloma with thalidomide and immunomodulatory drugs].
Hattori Y
Nihon Rinsho; 2007 Jan; 65 Suppl 1():596-600. PubMed ID: 17476758
[No Abstract] [Full Text] [Related]
55. Immunomodulatory drugs and the risk of serious infection in multiple myeloma: systematic review and meta-analysis of randomized and observational studies.
Chen M; Zhao Y; Xu C; Wang X; Zhang X; Mao B
Ann Hematol; 2018 Jun; 97(6):925-944. PubMed ID: 29500711
[TBL] [Abstract][Full Text] [Related]
56. [Thalidomide: mechanisms of action and new insights in hematology].
Leleu X; Micol JB; Guieze R; Berthon C; Kuhnovsky F; Terriou L; Moreau AS; Yakoub-Agha I; Bauters F; Facon T
Rev Med Interne; 2005 Feb; 26(2):119-27. PubMed ID: 15710258
[TBL] [Abstract][Full Text] [Related]
57. [Thalidomide, cereblon and multiple myeloma].
Ogura T
Nihon Rinsho; 2015 Jan; 73(1):149-55. PubMed ID: 25626321
[TBL] [Abstract][Full Text] [Related]
58. Thalidomide in the treatment of relapsed multiple myeloma.
Rajkumar SV; Fonseca R; Dispenzieri A; Lacy MQ; Lust JA; Witzig TE; Kyle RA; Gertz MA; Greipp PR
Mayo Clin Proc; 2000 Sep; 75(9):897-901. PubMed ID: 10994824
[TBL] [Abstract][Full Text] [Related]
59. [Immunomodulator drugs for the treatment of multiple myeloma].
Fernández-Lázaro D; Fernández-Lázaro CI; Caballero García A; Córdova Martínez A
Rev Med Chil; 2018 Dec; 146(12):1444-1451. PubMed ID: 30848748
[TBL] [Abstract][Full Text] [Related]
60. [Thalidomide in the treatment of refractory multiple myeloma: a Dutch study of 72 patients: an antitumor effect in 45%].
Wu KL; Schaafsma MR; Lokhorst HM; Wijermans PW; van der Holt B; Sonneveld P
Ned Tijdschr Geneeskd; 2002 Aug; 146(31):1445-8. PubMed ID: 12190011
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
